Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Ligand Pharmaceuticals Incorporated - Common Stock
(NQ:
LGND
)
218.98
+1.23 (+0.56%)
Streaming Delayed Price
Updated: 11:08 AM EDT, May 21, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Ligand Pharmaceuticals Incorporated - Common Stock
< Previous
1
2
3
4
Next >
Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
May 12, 2026
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement
May 06, 2026
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX), Soleno Therapeutics, Inc. (Nasdaq – SLNO)
May 05, 2026
From
Brodsky & Smith LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX), Soleno Therapeutics, Inc. (Nasdaq – SLNO)
April 27, 2026
From
Brodsky & Smith LLC
Via
GlobeNewswire
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
April 27, 2026
From
XOMA Royalty Corporation
Via
GlobeNewswire
Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates
November 10, 2025
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed
July 31, 2025
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
February 13, 2025
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 06, 2025
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance
December 10, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand to Present at Stifel 2024 Healthcare Conference
November 14, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance
November 07, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston
November 01, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024
October 23, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer
October 17, 2024
Mr. Korenberg is a seasoned executive with significant operational and financial leadership experience, including senior roles at Ligand Pharmaceuticals (NASDAQ: LGND) and in healthcare investment...
From
Palvella Therapeutics
Via
GlobeNewswire
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
September 06, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference
August 20, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Reports Second Quarter 2024 Financial Results
August 06, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand to Report Second Quarter 2024 Financial Results on August 6, 2024
July 23, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
5 Best Short-Term Stocks to Consider Investing In
July 10, 2024
Looking for the best short-term stocks? Explore our top picks and learn how to navigate the risks and opportunities in fast-paced stock trading.
Via
MarketBeat
Ligand to Acquire APEIRON Biologics AG for $100 Million
July 08, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Lifecore Biomedical Announces Cooperation Agreement with 22NW
July 01, 2024
Provides for the Addition of 22NW Nominees Jason Aryeh and Matthew Korenberg, as Well as Humberto Antunes and Paul Johnson, to the Board
From
Lifecore Biomedical, Inc.
Via
GlobeNewswire
Ligand Partner Verona Pharma Announces FDA Approval of Ohtuvayre™ (ensifentrine), First Inhaled Novel Mechanism for Maintenance Treatment of COPD in More Than 20 Years
June 27, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Adults
June 18, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand to Participate in Upcoming Investor Conferences
May 23, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Reports First Quarter 2024 Financial Results
May 07, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement
May 07, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand to Report First Quarter 2024 Financial Results on May 7, 2024
April 23, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference
April 08, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™
April 03, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
